AR122677A1 - Nuevos compuestos de dicianuro de heterociclil-carbonohidrazonoílo fusionado y su uso - Google Patents
Nuevos compuestos de dicianuro de heterociclil-carbonohidrazonoílo fusionado y su usoInfo
- Publication number
- AR122677A1 AR122677A1 ARP210101681A ARP210101681A AR122677A1 AR 122677 A1 AR122677 A1 AR 122677A1 AR P210101681 A ARP210101681 A AR P210101681A AR P210101681 A ARP210101681 A AR P210101681A AR 122677 A1 AR122677 A1 AR 122677A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- hydrogen
- independently
- carbonhydrazonoyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporcionan nuevos compuestos de dicianuro de heterociclil-carbonohidrazonoílo fusionado nuevo y usos de los mismos. Reivindicación 1: Un compuesto representado por la siguiente fórmula (1) o una de sus sales farmacéuticamente aceptables: en el que, en la fórmula (1), X¹ a X³ son cada uno de modo independiente N o C(H); Y¹ e Y² son cada uno de modo independiente N(R⁴), C(H), O, o S; n es 0 ó 1; ⁻ ⁻ ⁻ ⁻ ⁻ ⁻ es ₋₋₋₋₋₋ o ₌₌₌₌₌₌ que forma un anillo heterocíclico fusionado aromático o no aromático; R¹ es hidrógeno, alquilo C₁₋₆, o alquil C₁₋₆carbonilo; R² y R³ son cada uno de modo independiente hidrógeno, alquilo C₁₋₆, halógeno, ciano, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, alquil C₁₋₆amino, di(alquil C₁₋₆)amino, alquil C₁₋₆aminocarbonilo, o di(alquil C₁₋₆)aminocarbonilo; y R⁴ es hidrógeno, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₀₋₆, haloalquilo C₁₋₆, cicloalquil C₀₋₆-alquilo C₀₋₆, heterociclo-alquil C₀₋₆ de 5 ó 6 miembros, arilo C₆₋₁₀, o heteroarilo de 5 a 10 miembros, en el que el heterociclo de 5 ó 6 miembros, arilo C₆₋₁₀, y el heterociclo de 5 a 10 miembros están no sustituidos o sustituidos con alcoxi C₁₋₆ o alcoxi C₁₋₆carbonilo. Reivindicación 8: Un procedimiento de preparación del compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 7, el procedimiento que comprende: una primera etapa de reacción de un compuesto representado por la siguiente fórmula (2) que incluye un grupo amino reactivo en un extremo con nitrito de sodio y malononitrilo en presencia de un ácido para formar un enlace imina, y opcionalmente, una segunda etapa de introducción de un sustituyente R¹ en un producto obtenido en la etapa previa cuando R¹ es un sustituyente diferente de hidrógeno, en el que, en la fórmula (5) anterior X¹ a X³, Y¹, Y², n, ⁻ ⁻ ⁻ ⁻ ⁻ ⁻, R², y R³ son como se definieron en la reivindicación 1, y cuando Y¹ e Y² son N(H), N(H) está protegido por un terc-butoxicarbonilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200075041 | 2020-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122677A1 true AR122677A1 (es) | 2022-09-28 |
Family
ID=79178420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101681A AR122677A1 (es) | 2020-06-19 | 2021-06-18 | Nuevos compuestos de dicianuro de heterociclil-carbonohidrazonoílo fusionado y su uso |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230295095A1 (es) |
| EP (1) | EP4169905A4 (es) |
| JP (1) | JP2023530337A (es) |
| KR (1) | KR102633087B1 (es) |
| CN (1) | CN115867277A (es) |
| AR (1) | AR122677A1 (es) |
| AU (1) | AU2021291666B2 (es) |
| BR (1) | BR112022025610A2 (es) |
| CA (1) | CA3182243A1 (es) |
| MX (1) | MX2022016103A (es) |
| TW (1) | TWI794843B (es) |
| WO (1) | WO2021256899A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002333114B2 (en) * | 2001-11-30 | 2008-09-04 | Qlt Inc. | Hydrazonopyrazole derivatives and their use as therapeutics |
| GB0419416D0 (en) | 2004-09-01 | 2004-10-06 | Inst Of Ex Botany Ascr | 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| KR101910153B1 (ko) * | 2016-11-04 | 2018-10-19 | 한국과학기술연구원 | 타우 관련 질환의 예방 또는 치료용 레보시멘단 화합물 |
| EP3424908A1 (en) * | 2017-07-07 | 2019-01-09 | Melody Healthcare Pvt. Ltd. | Process for preparation of levosimendan |
| US9962384B1 (en) * | 2017-09-07 | 2018-05-08 | Korea Institute Of Science And Technology | Levosimendan compound for preventing or treating tau-related diseases |
| KR102128509B1 (ko) * | 2018-12-19 | 2020-07-01 | 한국과학기술연구원 | 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도 |
-
2021
- 2021-06-18 US US18/011,459 patent/US20230295095A1/en active Pending
- 2021-06-18 MX MX2022016103A patent/MX2022016103A/es unknown
- 2021-06-18 KR KR1020210079536A patent/KR102633087B1/ko active IP Right Grant
- 2021-06-18 AU AU2021291666A patent/AU2021291666B2/en active Active
- 2021-06-18 EP EP21825235.1A patent/EP4169905A4/en active Pending
- 2021-06-18 BR BR112022025610A patent/BR112022025610A2/pt unknown
- 2021-06-18 AR ARP210101681A patent/AR122677A1/es unknown
- 2021-06-18 CA CA3182243A patent/CA3182243A1/en active Pending
- 2021-06-18 JP JP2022577394A patent/JP2023530337A/ja active Pending
- 2021-06-18 WO PCT/KR2021/007691 patent/WO2021256899A1/ko active Application Filing
- 2021-06-18 TW TW110122474A patent/TWI794843B/zh active
- 2021-06-18 CN CN202180050485.3A patent/CN115867277A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115867277A (zh) | 2023-03-28 |
| KR102633087B1 (ko) | 2024-02-05 |
| CA3182243A1 (en) | 2021-12-23 |
| KR20210157360A (ko) | 2021-12-28 |
| AU2021291666A1 (en) | 2023-02-02 |
| EP4169905A1 (en) | 2023-04-26 |
| AU2021291666B2 (en) | 2024-06-20 |
| TWI794843B (zh) | 2023-03-01 |
| BR112022025610A2 (pt) | 2023-01-03 |
| US20230295095A1 (en) | 2023-09-21 |
| EP4169905A4 (en) | 2024-07-17 |
| WO2021256899A1 (ko) | 2021-12-23 |
| JP2023530337A (ja) | 2023-07-14 |
| TW202200548A (zh) | 2022-01-01 |
| MX2022016103A (es) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021000808A2 (es) | Agente profiláctico o terapéutico para atrofia muscular espinal | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
| PH12016501066A1 (en) | ROR GAMMA (ROYy) MODULATORS | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| PE20190437A1 (es) | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| ES2564010T3 (es) | Composición farmacéutica para tratar o prevenir el glaucoma | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR102213A1 (es) | Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR057063A1 (es) | Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica | |
| AR075367A1 (es) | Inhibidores de glucosilceramida sintasa | |
| AR052898A1 (es) | Derivados de la n-[(4,5-difenil -2-tienil) metil] amina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para enfermedades mediadas por los receptores canabinoides cb1 | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR115007A1 (es) | Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos | |
| AR090376A1 (es) | Compuestos herbicidas |